Modulating inflammation for cancer therapy

Journal of Experimental Medicine

Volumn 216, Issue 6, 2019, Pages 1234-1243

  Ritter, Birgit ^a   Greten, Florian R ^a,b,c  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE INHIBITOR;

CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER THERAPY; CELL ACTIVATION; CELL INFILTRATION; CHRONIC INFLAMMATION; HUMAN; IMMUNOCOMPETENT CELL; MALIGNANT NEOPLASM; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; NEOPLASM; PATHOLOGY;

ANIMALS; HUMANS; IMMUNOTHERAPY; INFLAMMATION; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85067218401     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20181739     Document Type: Review

References (128)

1. Arkan, M.C. 2017. The intricate connection between diet, microbiota, and cancer: A jigsaw puzzle. Semin. Immunol. 32:35–42. https://doi.org/10.1016/j.smim.2017.08.009
2. Bajor, D.L., R. Mick, M.J. Riese, A.C. Huang, B. Sullivan, L.P. Richman, D.A. Torigian, S.M. George, E. Stelekati, F. Chen, et al 2018. Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. OncoImmunology. 7: e1468956. https://doi.org/10.1080/2162402X.2018.1468956
3. Balkwill, F., and A. Mantovani. 2001. Inflammation and cancer: back to Virchow? Lancet. 357:539–545. https://doi.org/10.1016/S0140-6736(00) 04046-0
4. Balkwill, F.R., and A. Mantovani. 2012. Cancer-related inflammation: common themes and therapeutic opportunities. Semin. Cancer Biol. 22: 33–40. https://doi.org/10.1016/j.semcancer.2011.12.005
5. Beatty, G.L., E.G. Chiorean, M.P. Fishman, B. Saboury, U.R. Teitelbaum, W. Sun, R.D. Huhn, W. Song, D. Li, L.L. Sharp, et al 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 331:1612–1616. https://doi.org/10.1126/science.1198443
6. Bonapace, L., M.M. Coissieux, J. Wyckoff, K.D. Mertz, Z. Varga, T. Junt, and M. Bentires-Alj. 2014. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. 515:130–133. https://doi.org/10.1038/nature13862
7. Byrne, K.T., and R.H. Vonderheide. 2016. CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. Cell Reports. 15: 2719–2732. https://doi.org/10.1016/j.celrep.2016.05.058
8. Calon, A., E. Espinet, S. Palomo-Ponce, D.V. Tauriello, M. Iglesias, M.V. Céspedes, M. Sevillano, C. Nadal, P. Jung, X.H. Zhang, et al 2012. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell. 22:571–584. https://doi.org/10.1016/j.ccr.2012.08.013
9. Calon, A., E. Lonardo, A. Berenguer-Llergo, E. Espinet, X. Hernando-Momblona, M. Iglesias, M. Sevillano, S. Palomo-Ponce, D.V. Tauriello, D. Byrom, et al 2015. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47:320–329. https://doi.org/10.1038/ng.3225
10. Canli, Ö., A.M. Nicolas, J. Gupta, F. Finkelmeier, O. Goncharova, M. Pesic, T. Neumann, D. Horst, M. Löwer, U. Sahin, and F.R. Greten. 2017. Myeloid Cell-Derived Reactive Oxygen Species Induce Epithelial Mutagenesis. Cancer Cell. 32:869–883.e5. https://doi.org/10.1016/j.ccell.2017.11.004
11. Cannarile, M.A., M. Weisser, W. Jacob, A.M. Jegg, C.H. Ries, and D. Rüttinger. 2017. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J. Immunother. Cancer. 5:53. https://doi.org/10.1186/s40425-017-0257-y
12. Castaño, Z., B.P. San Juan, A. Spiegel, A. Pant, M.J. DeCristo, T. Laszewski, J.M. Ubellacker, S.R. Janssen, A. Dongre, F. Reinhardt, et al 2018. IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization. Nat. Cell Biol. 20:1084–1097. https://doi.org/10.1038/s41556-018-0173-5
13. Chao, M.P., A.A. Alizadeh, C. Tang, J.H. Myklebust, B. Varghese, S. Gill, M. Jan, A.C. Cha, C.K. Chan, B.T. Tan, et al 2010. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 142:699–713. https://doi.org/10.1016/j.cell.2010.07.044
14. Chen, D.S., and I. Mellman. 2017. Elements of cancer immunity and the cancer-immune set point. Nature. 541:321–330. https://doi.org/10.1038/ nature21349
15. Chen, W.Y., and M.D. Holmes. 2017. Role of Aspirin in Breast Cancer Survival. Curr. Oncol. Rep. 19:48. https://doi.org/10.1007/s11912-017-0605-6
16. Chesney, J., I. Puzanov, F. Collichio, P. Singh, M.M. Milhem, J. Glaspy, O. Hamid, M. Ross, P. Friedlander, C. Garbe, et al 2018. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J. Clin. Oncol. 36:1658–1667. https://doi.org/10.1200/JCO.2017.73.7379
17. Chung, H., S.J. Pamp, J.A. Hill, N.K. Surana, S.M. Edelman, E.B. Troy, N.C. Reading, E.J. Villablanca, S. Wang, J.R. Mora, et al 2012. Gut immune maturation depends on colonization with a host-specific microbiota. Cell. 149:1578–1593. https://doi.org/10.1016/j.cell.2012.04.037
18. Coley, W.B. 1893. The Treatment of Malignant Tumors by Repeated Innoculations of Erysipelas: With a Report of Ten Original Cases. Am. J. Med. Sci. 10:487–511. https://doi.org/10.1097/00000441-189305000-00001
19. Dagenais, M., J. Dupaul-Chicoine, T. Douglas, C. Champagne, A. Morizot, and M. Saleh. 2017. The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis. OncoImmunology. 6:e1287247. https://doi.org/10.1080/2162402X.2017.1287247
20. Demicheli, R., M.W. Retsky, W.J. Hrushesky, M. Baum, and I.D. Gukas. 2008. The effects of surgery on tumor growth: a century of investigations. Ann. Oncol. 19:1821–1828. https://doi.org/10.1093/annonc/mdn386
21. Dempke, W.C.M., K. Fenchel, P. Uciechowski, and S.P. Dale. 2017. Second- and third-generation drugs for immuno-oncology treatment-The more the better? Eur. J. Cancer. 74:55–72. https://doi.org/10.1016/j.ejca.2017.01.001
22. DeNardo, D.G., D.J. Brennan, E. Rexhepaj, B. Ruffell, S.L. Shiao, S.F. Madden, W.M. Gallagher, N. Wadhwani, S.D. Keil, S.A. Junaid, et al 2011. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1:54–67. https://doi.org/10.1158/2159-8274.CD-10-0028
23. Deng, J., E.S. Wang, R.W. Jenkins, S. Li, R. Dries, J. Yates, S. Chhabra, W. Huang, H. Liu, A.R. Aref, et al 2018. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 8: 216–233. https://doi.org/10.1158/2159-8290
24. Deng, L., H. Liang, M. Xu, X. Yang, B. Burnette, A. Arina, X.D. Li, H. Mauceri, M. Beckett, T. Darga, et al 2014. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 41:843–852. https://doi.org/10.1016/j.immuni.2014.10.019
25. Dijkstra, K.K., C.M. Cattaneo, F. Weeber, M. Chalabi, J. van de Haar, L.F. Fanchi, M. Slagter, D.L. van der Velden, S. Kaing, S. Kelderman, et al 2018. Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell. 174:1586–1598.e12. https://doi.org/10.1016/j.cell.2018.07.009
26. Dinarello, C.A., A. Simon, and J.W. van der Meer. 2012. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11:633–652. https://doi.org/10.1038/nrd3800
27. Fabre, J., J. Giustiniani, C. Garbar, F. Antonicelli, Y. Merrouche, A. Bensussan, M. Bagot, and R. Al-Dacak. 2016. Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type. Int. J. Mol. Sci. 17:1433. https://doi.org/10.3390/ijms17091433
28. Faguet, G.B. 2015. A brief history of cancer: age-old milestones underlying our current knowledge database. Int. J. Cancer. 136:2022–2036. https://doi.org/10.1002/ijc.29134
29. Ferrara, N., K.J. Hillan, H.P. Gerber, and W. Novotny. 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3:391–400. https://doi.org/10.1038/nrd1381
30. Fraga, M.F., E. Ballestar, A. Villar-Garea, M. Boix-Chornet, J. Espada, G. Schotta, T. Bonaldi, C. Haydon, S. Ropero, K. Petrie, et al 2005. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37:391–400. https://doi.org/10.1038/ng1531
31. Frouws, M.A., M.P.P. van Herk-Sukel, H.A. Maas, C.J.H. Van de Velde, J.E.A. Portielje, G.J. Liefers, and E. Bastiaannet. 2017. The mortality reducing effect of aspirin in colorectal cancer patients: Interpreting the evidence. Cancer Treat. Rev. 55:120–127. https://doi.org/10.1016/j.ctrv.2016.12.008
32. Gajewski, T.F. 2015. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin. Oncol. 42:663–671. https://doi.org/10.1053/j.seminoncol.2015.05.011
33. Geller, L.T., M. Barzily-Rokni, T. Danino, O.H. Jonas, N. Shental, D. Nejman, N. Gavert, Y. Zwang, Z.A. Cooper, K. Shee, et al 2017. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 357:1156–1160. https://doi.org/10.1126/science.aah5043
34. Germano, G., R. Frapolli, C. Belgiovine, A. Anselmo, S. Pesce, M. Liguori, E. Erba, S. Uboldi, M. Zucchetti, F. Pasqualini, et al 2013. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 23: 249–262. https://doi.org/10.1016/j.ccr.2013.01.008
35. Gholamin, S., S.S. Mitra, A.H. Feroze, J. Liu, S.A. Kahn, M. Zhang, R. Esparza, C. Richard, V. Ramaswamy, M. Remke, et al 2017. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci. Transl. Med. 9:eaaf2968. https://doi.org/10.1126/scitranslmed.aaf2968
36. Goel, A., and C.R. Boland. 2012. Epigenetics of colorectal cancer. Gastroenterology. 143:1442–1460.e1. https://doi.org/10.1053/j.gastro.2012.09.032
37. Goel, S., M.J. DeCristo, A.C. Watt, H. BrinJones, J. Sceneay, B.B. Li, N. Khan, J.M. Ubellacker, S. Xie, O. Metzger-Filho, et al 2017. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 548:471–475. https://doi.org/10.1038/nature23465
38. Gopalakrishnan, V., C.N. Spencer, L. Nezi, A. Reuben, M.C. Andrews, T.V. Karpinets, P.A. Prieto, D. Vicente, K. Hoffman, S.C. Wei, et al 2018. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 359:97–103. https://doi.org/10.1126/science.aan4236
39. Gordon, S.R., R.L. Maute, B.W. Dulken, G. Hutter, B.M. George, M.N. McCracken, R. Gupta, J.M. Tsai, R. Sinha, D. Corey, et al 2017. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 545:495–499. https://doi.org/10.1038/ nature22396
40. Goto, H., Y. Kojima, K. Matsuda, R. Kariya, M. Taura, K. Kuwahara, H. Nagai, H. Katano, and S. Okada. 2014. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma. Eur. J. Cancer. 50:1836–1846. https://doi.org/10.1016/j.ejca.2014.03.004
41. Greten, F.R., M.C. Arkan, J. Bollrath, L.C. Hsu, J. Goode, C. Miething, S.I. Göktuna, M. Neuenhahn, J. Fierer, S. Paxian, et al 2007. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell. 130:918–931. https://doi.org/10.1016/j.cell.2007.07.009
42. Grivennikov, S.I., F.R. Greten, and M. Karin. 2010. Immunity, inflammation, and cancer. Cell. 140:883–899. https://doi.org/10.1016/j.cell.2010.01.025
43. Guerriero, J.L., A. Sotayo, H.E. Ponichtera, J.A. Castrillon, A.L. Pourzia, S. Schad, S.F. Johnson, R.D. Carrasco, S. Lazo, R.T. Bronson, et al 2017. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature. 543:428–432. https://doi.org/10.1038/nature21409
44. Gunderson, A.J., M.M. Kaneda, T. Tsujikawa, A.V. Nguyen, N.I. Affara, B. Ruffell, S. Gorjestani, S.M. Liudahl, M. Truitt, P. Olson, et al 2016. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discov. 6:270–285. https://doi.org/10.1158/2159-8290.CD-15-0827
45. Guo, B., S. Fu, J. Zhang, B. Liu, and Z. Li. 2016. Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Sci. Rep. 6:36107. https://doi.org/10.1038/srep36107
46. Hanahan, D. 2014. Rethinking the war on cancer. Lancet. 383:558–563. https://doi.org/10.1016/S0140-6736(13)62226-6
47. Haque, S., and J.C. Morris. 2017. Transforming growth factor-β: A therapeutic target for cancer. Hum. Vaccin. Immunother. 13:1741–1750. https://doi.org/10.1080/21645515.2017.1327107
48. Harding, S.M., J.L. Benci, J. Irianto, D.E. Discher, A.J. Minn, and R.A. Greenberg. 2017. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature. 548:466–470. https://doi.org/10.1038/nature23470
49. Hartley, G.P., L. Chow, D.T. Ammons, W.H. Wheat, and S.W. Dow. 2018. Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation. Cancer Immunol. Res. 6:1260–1273. https://doi.org/10.1158/2326-6066.CIR-17-0537
50. Hengel, S.R., M.A. Spies, and M. Spies. 2017. Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy. Cell Chem. Biol. 24:1101–1119. https://doi.org/10.1016/j.chembiol.2017.08.027
51. Henschke, U.K., G.J. Luande, and J.D. Choppala. 1977. Aspirin for reducing cancer metastases? J. Natl. Med. Assoc. 69:581–584.
52. Hofer, S.O., D. Shrayer, J.S. Reichner, H.J. Hoekstra, and H.J. Wanebo. 1998. Wound-induced tumor progression: a probable role in recurrence after tumor resection. Arch. Surg. 133:383–389. https://doi.org/10.1001/archsurg.133.4.383
53. Hoves, S., C.H. Ooi, C. Wolter, H. Sade, S. Bissinger, M. Schmittnaegel, O. Ast, A.M. Giusti, K. Wartha, V. Runza, et al 2018. Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. J. Exp. Med. 215:859–876. https://doi.org/10.1084/jem.20171440
54. Hu-Lieskovan, S., and A. Ribas. 2017. New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. Cancer J. 23:10–22. https://doi.org/10.1097/PPO.0000000000000246
55. Iida, N., A. Dzutsev, C.A. Stewart, L. Smith, N. Bouladoux, R.A. Weingarten, D.A. Molina, R. Salcedo, T. Back, S. Cramer, et al 2013. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 342:967–970. https://doi.org/10.1126/science.1240527
56. Ishizuka, J.J., R.T. Manguso, C.K. Cheruiyot, K. Bi, A. Panda, A. Iracheta-Vellve, B.C. Miller, P.P. Du, K.B. Yates, J. Dubrot, et al 2019. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature. 565:43–48. https://doi.org/10.1038/s41586-018-0768-9
57. Jacobs, C.D., S.G. Chun, J. Yan, X.J. Xie, D.A. Pistenmaa, R. Hannan, Y. Lotan, C.G. Roehrborn, K.S. Choe, and D.W. Kim. 2014. Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy. Cancer Biol. Ther. 15:699–706. https://doi.org/10.4161/cbt.28554
58. Jain, R.K. 2001. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7:987–989. https://doi.org/10.1038/nm0901-987
59. Jiang, T., C. Zhou, and S. Ren. 2016. Role of IL-2 in cancer immunotherapy. OncoImmunology. 5:e1163462. https://doi.org/10.1080/2162402X.2016.1163462
60. Johansson-Percival, A., B. He, Z.J. Li, A. Kjellén, K. Russell, J. Li, I. Larma, and R. Ganss. 2017. De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat. Immunol. 18:1207–1217. https://doi.org/10.1038/ni.3836
61. Johnson, D.E., R.A. O’Keefe, and J.R. Grandis. 2018. Targeting the IL-6/JAK/ STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15:234–248. https://doi.org/10.1038/nrclinonc.2018.8
62. Kali, A. 2015. TNFerade, an innovative cancer immunotherapeutic. Indian J. Pharmacol. 47:479–483. https://doi.org/10.4103/0253-7613.165190
63. Kaneda, M.M., K.S. Messer, N. Ralainirina, H. Li, C.J. Leem, S. Gorjestani, G. Woo, A.V. Nguyen, C.C. Figueiredo, P. Foubert, et al 2016. PI3Kγ is a molecular switch that controls immune suppression. Nature. 539: 437–442. https://doi.org/10.1038/nature19834
64. Kitamura, H., Y. Ohno, Y. Toyoshima, J. Ohtake, S. Homma, H. Kawamura, N. Takahashi, and A. Taketomi. 2017. Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci. 108:1947–1952. https://doi.org/10.1111/cas.13332
65. Klement, G., S. Baruchel, J. Rak, S. Man, K. Clark, D.J. Hicklin, P. Bohlen, and R.S. Kerbel. 2000. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105:R15–R24. https://doi.org/10.1172/ JCI8829
66. Kozłowska, R., A. Bozek, and J. Jarzab. 2016. Association between cancer and allergies. Allergy Asthma Clin. Immunol. 12:39. https://doi.org/10.1186/ s13223-016-0147-8
67. Kryczek, I., S. Wei, W. Szeliga, L. Vatan, and W. Zou. 2009. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood. 114: 357–359. https://doi.org/10.1182/blood-2008-09-177360
68. Kumai, T., H. Kobayashi, Y. Harabuchi, and E. Celis. 2017. Peptide vaccines in cancer-old concept revisited. Curr. Opin. Immunol. 45:1–7. https://doi.org/10.1016/j.coi.2016.11.001
69. Kurahara, H., H. Shinchi, Y. Mataki, K. Maemura, H. Noma, F. Kubo, M. Sakoda, S. Ueno, S. Natsugoe, and S. Takao. 2011. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J. Surg. Res. 167:e211–e219. https://doi.org/10.1016/j.jss.2009.05.026
70. Le, D.T., E. Lutz, J.N. Uram, E.A. Sugar, B. Onners, S. Solt, L. Zheng, L.A. Diaz Jr., R.C. Donehower, E.M. Jaffee, and D.A. Laheru. 2013. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 36:382–389. https://doi.org/10.1097/CJI.0b013e31829fb7a2
71. Lee, J., and S.H. Huang. 2013. Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor, Vorinostat. Chemotherapy (Los Angel.). 2:14934.
72. Lee, S., and K. Margolin. 2011. Cytokines in cancer immunotherapy. Cancers (Basel). 3:3856–3893. https://doi.org/10.3390/cancers3043856
73. Li, K., S. Qu, X. Chen, Q. Wu, and M. Shi. 2017. Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways. Int. J. Mol. Sci. 18:E404. https://doi.org/10.3390/ijms18020404
74. Lim, C., D. Broqueres-You, J.P. Brouland, T. Merkulova-Rainon, A.M. Faussat, R. Hilal, D. Rouquie, C. Eveno, R. Audollent, B.I. Levy, and M. Pocard. 2013. Hepatic ischemia-reperfusion increases circulating bone marrow-derived progenitor cells and tumor growth in a mouse model of colorectal liver metastases. J. Surg. Res. 184:888–897. https://doi.org/10.1016/j.jss.2013.04.069
75. Lim, S.Y., A.E. Yuzhalin, A.N. Gordon-Weeks, and R.J. Muschel. 2016. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget. 7: 28697–28710. https://doi.org/10.18632/oncotarget.7376
76. Liu, R., H. Wei, P. Gao, H. Yu, K. Wang, Z. Fu, B. Ju, M. Zhao, S. Dong, Z. Li, et al 2017. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis. Oncotarget. 8:39021–39032.
77. Liu, Y., Y. Dong, L. Kong, F. Shi, H. Zhu, and J. Yu. 2018. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J. Hematol. Oncol. 11:104. https://doi.org/10.1186/s13045-018-0647-8
78. Majety, M., V. Runza, C. Lehmann, S. Hoves, and C.H. Ries. 2018. A drug development perspective on targeting tumor-associated myeloid cells. FEBS J. 285:763–776. https://doi.org/10.1111/febs.14277
79. Manguso, R.T., H.W. Pope, M.D. Zimmer, F.D. Brown, K.B. Yates, B.C. Miller, N.B. Collins, K. Bi, M.W. LaFleur, V.R. Juneja, et al 2017. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 547:413–418. https://doi.org/10.1038/nature23270
80. Mankan, A.K., O. Canli, S. Schwitalla, P. Ziegler, J. Tschopp, T. Korn, and F.R. Greten. 2011. TNF-alpha-dependent loss of IKKbeta-deficient myeloid progenitors triggers a cytokine loop culminating in granulocytosis. Proc. Natl. Acad. Sci. USA. 108:6567–6572. https://doi.org/10.1073/pnas .1018331108
81. Mariathasan, S., S.J. Turley, D. Nickles, A. Castiglioni, K. Yuen, Y. Wang, E.E. Kadel III, H. Koeppen, J.L. Astarita, R. Cubas, et al 2018. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 554:544–548. https://doi.org/10.1038/nature25501
82. McCubrey, J.A., L.S. Steelman, W.H. Chappell, S.L. Abrams, R.A. Franklin, G. Montalto, M. Cervello, M. Libra, S. Candido, G. Malaponte, et al 2012. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget. 3:1068–1111. https://doi.org/10.18632/oncotarget.659
83. Medrano, R.F.V., A. Hunger, S.A. Mendonça, J.A.M. Barbuto, and B.E. Strauss. 2017. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget. 8:71249–71284. https://doi.org/10.18632/oncotarget.19531
84. Métayer, L.E., A. Vilalta, G.A.A. Burke, and G.C. Brown. 2017. Anti-CD47 antibodies induce phagocytosis of live, malignant B cells by macrophages via the Fc domain, resulting in cell death by phagoptosis. Oncotarget. 8:60892–60903. https://doi.org/10.18632/oncotarget.18492
85. Molgora, M., D. Supino, A. Mantovani, and C. Garlanda. 2018. Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8. Immunol. Rev. 281:233–247. https://doi.org/10.1111/imr.12609
86. Murthy, S.M., R.A. Goldschmidt, L.N. Rao, M. Ammirati, T. Buchmann, and E.F. Scanlon. 1989. The influence of surgical trauma on experimental metastasis. Cancer. 64:2035–2044. https://doi.org/10.1002/1097-0142(19891115)64:10<2035::AID-CNCR2820641012>3.0.CO;2-L
87. Naing, A., K.P. Papadopoulos, K.A. Autio, P.A. Ott, M.R. Patel, D.J. Wong, G.S. Falchook, S. Pant, M. Whiteside, D.R. Rasco, et al 2016. Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. J. Clin. Oncol. 34:3562–3569. https://doi.org/10.1200/JCO.2016.68.1106
88. Naing, A., J.R. Infante, K.P. Papadopoulos, I.H. Chan, C. Shen, N.P. Ratti, B. Rojo, K.A. Autio, D.J. Wong, M.R. Patel, et al 2018. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer Cell. 34:775–791.e3. https://doi.org/10.1016/j.ccell.2018.10.007
89. Oft, M. 2014. IL-10: master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol. Res. 2:194–199. https://doi.org/10.1158/2326-6066.CIR-13-0214
90. Palucka, K., and J. Banchereau. 2013. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 39:38–48. https://doi.org/10.1016/j.immuni.2013.07.004
91. Patel, S.A., and A.J. Minn. 2018. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Immunity. 48: 417–433. https://doi.org/10.1016/j.immuni.2018.03.007
92. Peinado, H., H. Zhang, I.R. Matei, B. Costa-Silva, A. Hoshino, G. Rodrigues, B. Psaila, R.N. Kaplan, J.F. Bromberg, Y. Kang, et al 2017. Pre-metastatic niches: organ-specific homes for metastases. Nat. Rev. Cancer. 17: 302–317. https://doi.org/10.1038/nrc.2017.6
93. Perry, C.J., A.R. Muñoz-Rojas, K.M. Meeth, L.N. Kellman, R.A. Amezquita, D. Thakral, V.Y. Du, J.X. Wang, W. Damsky, A.L. Kuhlmann, et al 2018. Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. J. Exp. Med. 215:877–893. https://doi.org/10.1084/jem.20171435
94. Pyonteck, S.M., L. Akkari, A.J. Schuhmacher, R.L. Bowman, L. Sevenich, D.F. Quail, O.C. Olson, M.L. Quick, J.T. Huse, V. Teijeiro, et al 2013. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19:1264–1272. https://doi.org/10.1038/nm.3337
95. Qian, X., H. Chen, X. Wu, L. Hu, Q. Huang, and Y. Jin. 2017. Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis. Cytokine. 89:34–44. https://doi.org/10.1016/j.cyto.2015.09.011
96. Quail, D.F., and J.A. Joyce. 2013. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19:1423–1437. https://doi.org/10.1038/nm.3394
97. Quante, M., J. Varga, T.C. Wang, and F.R. Greten. 2013. The gastrointestinal tumor microenvironment. Gastroenterology. 145:63–78. https://doi.org/10.1053/j.gastro.2013.03.052
98. Raja, J., J.M. Ludwig, S.N. Gettinger, K.A. Schalper, and H.S. Kim. 2018. Oncolytic virus immunotherapy: future prospects for oncology. J. Immunother. Cancer. 6:140. https://doi.org/10.1186/s40425-018-0458-z
99. Rech, A.J., H. Dada, J.J. Kotzin, J. Henao-Mejia, A.J. Minn, C. Twyman-Saint Victor, and R.H. Vonderheide. 2018. Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer. Cancer Res. 78:4282–4291. https://doi.org/10.1158/0008-5472.CAN-17-3821
100. Ribas, A., R. Dummer, I. Puzanov, A. VanderWalde, R.H.I. Andtbacka, O. Michielin, A.J. Olszanski, J. Malvehy, J. Cebon, E. Fernandez, et al 2017. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 170:1109–1119.e10. https://doi.org/10.1016/j.cell.2017.08.027
101. Ridker, P.M., J.G. MacFadyen, T. Thuren, B.M. Everett, P. Libby, and R.J. Glynn. CANTOS Trial Group. 2017. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 390:1833–1842. https://doi.org/10.1016/S0140-6736(17)32247-X
102. Ries, C.H., M.A. Cannarile, S. Hoves, J. Benz, K. Wartha, V. Runza, F. Rey-Giraud, L.P. Pradel, F. Feuerhake, I. Klaman, et al 2014. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 25:846–859. https://doi.org/10.1016/j.ccr.2014.05.016
103. Rivera Vargas, T., I. Benoit-Lizon, and L. Apetoh. 2017. Rationale for stimulator of interferon genes-targeted cancer immunotherapy. Eur. J. Cancer. 75:86–97. https://doi.org/10.1016/j.ejca.2016.12.028
104. Robert, C., L. Thomas, I. Bondarenko, S. O’Day, J. Weber, C. Garbe, C. Lebbe, J.F. Baurain, A. Testori, J.J. Grob, et al 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364: 2517–2526. https://doi.org/10.1056/NEJMoa1104621
105. Ruffell, B., and L.M. Coussens. 2015. Macrophages and therapeutic resistance in cancer. Cancer Cell. 27:462–472. https://doi.org/10.1016/j.ccell.2015.02.015
106. Seidel, J.A., A. Otsuka, and K. Kabashima. 2018. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front. Oncol. 8:86. https://doi.org/10.3389/fonc.2018.00086
107. Shabo, I., O. Stål, H. Olsson, S. Doré, and J. Svanvik. 2008. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int. J. Cancer. 123: 780–786. https://doi.org/10.1002/ijc.23527
108. Simpson, T.R., F. Li, W. Montalvo-Ortiz, M.A. Sepulveda, K. Bergerhoff, F. Arce, C. Roddie, J.Y. Henry, H. Yagita, J.D. Wolchok, et al 2013. Fcdependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210:1695–1710. https://doi.org/10.1084/jem.20130579
109. Sivan, A., L. Corrales, N. Hubert, J.B. Williams, K. Aquino-Michaels, Z.M. Earley, F.W. Benyamin, Y.M. Lei, B. Jabri, M.L. Alegre, et al 2015. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 350:1084–1089. https://doi.org/10.1126/science.aac4255
110. Sontheimer-Phelps, A., B.A. Hassell, and D.E. Ingber. 2019. Modelling cancer in microfluidic human organs-on-chips. Nat. Rev. Cancer. 19:65–81. https://doi.org/10.1038/s41568-018-0104-6
111. Srivatsan, S., J.M. Patel, E.N. Bozeman, I.E. Imasuen, S. He, D. Daniels, and P. Selvaraj. 2014. Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum. Vaccin. Immunother. 10:52–63. https://doi.org/10.4161/hv.26568
112. Tanoue, T., S. Morita, D.R. Plichta, A.N. Skelly, W. Suda, Y. Sugiura, S. Narushima, H. Vlamakis, I. Motoo, K. Sugita, et al 2019. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature. 565:600–605. https://doi.org/10.1038/s41586-019-0878-z
113. Tauriello, D.V.F., S. Palomo-Ponce, D. Stork, A. Berenguer-Llergo, J. Badia-Ramentol, M. Iglesias, M. Sevillano, S. Ibiza, A. Cañellas, X. Hernando-Momblona, et al 2018. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 554:538–543. https://doi.org/10.1038/nature25492
114. Todoric, J., L. Antonucci, and M. Karin. 2016. Targeting Inflammation in Cancer Prevention and Therapy. Cancer Prev. Res. (Phila.). 9:895–905. https://doi.org/10.1158/1940-6207.CAPR-16-0209
115. Tohme, S., R.L. Simmons, and A. Tsung. 2017. Surgery for Cancer: A Trigger for Metastases. Cancer Res. 77:1548–1552. https://doi.org/10.1158/0008-5472.CAN-16-1536
116. Turner, M.C., Y. Chen, D. Krewski, and P. Ghadirian. 2006. An overview of the association between allergy and cancer. Int. J. Cancer. 118:3124–3132. https://doi.org/10.1002/ijc.21752
117. van den Eertwegh, A.J., J. Versluis, H.P. van den Berg, S.J. Santegoets, R.J. van Moorselaar, T.M. van der Sluis, H.E. Gall, T.C. Harding, K. Jooss, I. Lowy, et al 2012. Combined immunotherapy with granulocytemacrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 13:509–517. https://doi.org/10.1016/S1470-2045(12)70007-4
118. Varga, J., and F.R. Greten. 2017. Cell plasticity in epithelial homeostasis and tumorigenesis. Nat. Cell Biol. 19:1133–1141. https://doi.org/10.1038/ ncb3611
119. Vétizou, M., J.M. Pitt, R. Daillère, P. Lepage, N. Waldschmitt, C. Flament, S. Rusakiewicz, B. Routy, M.P. Roberti, C.P. Duong, et al 2015. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 350:1079–1084. https://doi.org/10.1126/science.aad1329
120. Viaud, S., F. Saccheri, G. Mignot, T. Yamazaki, R. Daillère, D. Hannani, D.P. Enot, C. Pfirschke, C. Engblom, M.J. Pittet, et al 2013. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 342:971–976. https://doi.org/10.1126/science.1240537
121. Vonderheide, R.H. 2018. The Immune Revolution: A Case for Priming, Not Checkpoint. Cancer Cell. 33:563–569. https://doi.org/10.1016/j.ccell.2018.03.008
122. + macrophage population in human gastric cancer that promotes disease progression. Oncogenesis. 7:41. https://doi.org/10.1038/s41389-018-0049-3
123. Wang, H., S. Hu, X. Chen, H. Shi, C. Chen, L. Sun, and Z.J. Chen. 2017. cGAS is essential for the antitumor effect of immune checkpoint blockade. Proc. Natl. Acad. Sci. USA. 114:1637–1642. https://doi.org/10.1073/pnas.1621363114
124. Wang, K., M.K. Kim, G. Di Caro, J. Wong, S. Shalapour, J. Wan, W. Zhang, Z. Zhong, E. Sanchez-Lopez, L.W. Wu, et al 2014. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity. 41:1052–1063. https://doi.org/10.1016/j.immuni.2014.11.009
125. Weinberg, R.A. 2014. Coming full circle-from endless complexity to simplicity and back again. Cell. 157:267–271. https://doi.org/10.1016/j.cell.2014.03.004
126. Whittaker, S.R., A. Mallinger, P. Workman, and P.A. Clarke. 2017. Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol. Ther. 173:83–105. https://doi.org/10.1016/j.pharmthera.2017.02.008
127. Zamarin, D., R.B. Holmgaard, S.K. Subudhi, J.S. Park, M. Mansour, P. Palese, T. Merghoub, J.D. Wolchok, and J.P. Allison. 2014. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6:226ra32. https://doi.org/10.1126/scitranslmed.3008095
128. Zitvogel, L., Y. Ma, D. Raoult, G. Kroemer, and T.F. Gajewski. 2018. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 359:1366–1370. https://doi.org/10.1126/science.aar6918